Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sitala Bio
Cambridge, England, United Kingdomsitala.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sitala Bio is developing therapies that block harmful inflammation, with an emphasis on neurodegenerative disorders such as Parkinson’s and Alzheimer’s. The company leverages advanced fragment-based drug discovery platforms. No public clinical results or late-stage assets are reported as of June 2025.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
Shake It Up Australia FoundationThe Michael J. Fox Foundation
Beyond the preview
Go deeper on Sitala Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sitala Bio.